| CAS登錄號 | 中文名 | 英文名 | 分子結(jié)構(gòu)式 | 分子式 | 詳情 | 供應(yīng)商 |
| 55077-30-0 | 萘二磺酸乙乳膽銨; 雙醋萘磺膽堿; 雙(乙酰氧基-甲基醋酸三甲胺乙酯)-萘-1,5-二磺酸鹽; 2-[2-(乙酰氧基)-1-氧丙 | ACLAtonium napadisilate; 2-(2-Acetyloxypropanoyloxy)ethyl-[2-[2-(2-acetyloxypropanoyloxy)ethyl-dimethyl-ammonio]ethyl]-dimethyl-azanium naphthalene-1,5-disulfonate |  | C30H44N2O14S2 | 詳情 | 供應(yīng)商 |
| 57576-44-0 | 阿克拉霉素; 阿柔比星 | ACLArubicin; Methyl (1R,2R,4S)-4-[(2R,5S,6S)-4-dimethylamino-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate |  | C42H53NO15 | 詳情 | 供應(yīng)商 |
| 84031-17-4 | 美他西泮; 7-溴-5-(2-氯苯基)-2,3-二氫-2-(甲氧基甲基)-1-甲基-1H-1,4-苯并二氮雜卓; 美他西泮 | 1H-1,4-Benzodiazepine,7-bromo-5-(2-chlorophenyl)-2,3-dihydro-2-(methoxymethyl)-1-methyl-; (?à)-MetACLAzepam; Brometazepam; KC2547; Ka 2547; MetACLAzepam; Metuclazepam; Talis; Talis (pharmaceutical) |  | C18H18BrClN2O | 詳情 | 供應(yīng)商 |
| 34061-33-1 | 1H-Benzo[6,7]cyclohepta[1,2,3-de]pyrido[2,1-a]isoquinoline,2,3,4,4a,8,9,13b,14-octahydro- (8CI,9CI); TACLAmine |  | C21H25N | 詳情 | 供應(yīng)商 | |
| 86298-26-2 | 1H-1,4-Benzodiazepine,7-bromo-5-(2-chlorophenyl)-2,3-dihydro-2-(methoxymethyl)-; NormetACLAzepam |  | C17H16BrClN2O | 詳情 | 供應(yīng)商 | |
| 91625-76-2 | 1H-1,4-Benzodiazepine,7-bromo-5-(2-chlorophenyl)-2,3-dihydro-2-methoxy-; N-DesmethylmetACLAzepam |  | C16H14BrClN2O | 詳情 | 供應(yīng)商 | |
| 75443-99-1 | 鹽酸阿柔比星 | ACLARUBICIN HYDROCHLORIDE; ACLARUBICIN HYDROCHLORIDE; ACLAcinomycinahydrochloride; ACLAcinon; n-2-yl)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyrano; syl)oxy)-2,5,7-trihydroxy-,methylester,hydrochloride,(1r-(1-alpha,2-beta,4; 1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-l-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-l-lyxo; 1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R,6S)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]-3-(dimethylamino)-α-L-lyxo-hexopyranosyl]oxy]-, meth; 1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]-3-(dimethylamino)-α-L-lyxo-hexopyranosyl]oxy]-, methyl ester, hydrochloride, [1R-(1α,2β,4β)]- |  | C42H54ClNO15 | 詳情 | 供應(yīng)商 |
| 55528-08-0 | (-)-ButACLAmol hydrochloride |  | 詳情 | 供應(yīng)商 | ||
| 55528-07-9 | (+)-ButACLAmol hydrochloride |  | 詳情 | 供應(yīng)商 | ||
| 1214735-16-6 | DACLATASVIR (BMS-790052) | BMS-790052; DACLAtasvir (BMS-790052) | 無 | 詳情 | 供應(yīng)商 | |
| 1404-52-0 | BetACLAmycin T; (7R)-8-Ethyl-7,8,9,10-tetrahydro-1,6,7,8α,11-pentahydroxy-10α-[(3-dimethylamino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-5,12-naphthacenedione; BetACLAmycin T; Rhodomycin B; β-Rhodomycin I | 無 | 詳情 | 供應(yīng)商 | ||